<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Optic pathway glioma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Optic pathway glioma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Optic pathway glioma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence D Recht, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen A Shih, MD, MS, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amar Gajjar, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Evelyn A Paysse, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Glenn A Tung, MD, FACR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 14, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optic pathway gliomas (OPGs; also referred to as optic gliomas) are low-grade astrocytic tumors that occur in the optic nerve, chiasm, or both. They occur sporadically and in patients with neurofibromatosis type 1 (NF1). Although often indolent, OPGs can cause clinical symptoms due to mass effect and visual loss.
        </p>
        <p>
         The classification, diagnosis, natural history, and management of OPGs will be reviewed here. Diagnosis and management of NF1 are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90123.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Management and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         OPGs account for approximately 2 percent of cerebral gliomas. They are typically slow-growing neoplasms that occur mainly in children, with 90 percent diagnosed before the age of 20 and 75 percent before the age of 10 [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         OPGs are classified by anatomic location and by whether or not they are associated with neurofibromatosis type 1 (NF1; von Recklinghausen disease).
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Location
         </span>
         <span class="headingEndMark">
          —
         </span>
         Low-grade gliomas may involve the anterior visual pathway (optic nerves or more anteriorly) in 25 to 35 percent of cases or the posterior visual pathway (chiasm and postchiasmal extension).
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Anterior visual pathway
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anterior tumors can be subdivided into orbital, intracanalicular, and intracranial prechiasmal lesions [
         <a href="#rid2">
          2
         </a>
         ]. These tumors occur most frequently in prepubescent children, and most are classified as pilocytic astrocytomas [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"
         </a>
         .)
        </p>
        <p>
         The tumor may appear as either an infiltrative lesion or one that is sharply demarcated from the normal optic nerve. Invasion of the leptomeninges or a dense fibroblastic reaction is frequently seen. As the tumor progresses, it compresses the optic nerve. As a result, the optic nerve becomes demyelinated and optic atrophy develops.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Posterior visual pathway
         </span>
         <span class="headingEndMark">
          —
         </span>
         Posterior tumors may arise in the optic chiasm, hypothalamus, or anterior third ventricle [
         <a href="#rid3">
          3
         </a>
         ]. Chiasmal and hypothalamic lesions present at a mean age of approximately three years. Histologically, these are typically pilocytic astrocytomas. Occasionally, gangliogliomas occur [
         <a href="#rid4">
          4-6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Association with neurofibromatosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         OPGs are the most common central nervous system tumors associated with NF1. If all children underwent screening, estimates indicate that OPGs would be found in 15 percent of those with NF1 [
         <a href="#rid7">
          7,8
         </a>
         ]. NF1 tumors more commonly involve the anterior visual pathway, while tumors in NF1-negative children are more frequent in the posterior visual pathway [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         The natural history and clinical presentation of OPGs in patients with NF1, along with the potential role of screening, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Optic pathway gliomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         OPGs are generally classified as low-grade astrocytomas, although they have a range of growth rates [
         <a href="#rid1">
          1
         </a>
         ]. For this reason, it had been suggested that some OPGs may be hamartomas [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         However, most evidence supports their designation as true, slow-growing neoplasms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         OPGs are virtually identical histologically to pilocytic astrocytomas seen elsewhere in the nervous system [
         <a href="#rid11">
          11
         </a>
         ]. Sporadic pilocytic astrocytomas often have a tandem duplication of chromosome 7q34 and associated
         <em>
          BRAF-KIAA
         </em>
         fusion gene, which is relevant for targeted therapy [
         <a href="#rid12">
          12,13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5202.html" rel="external">
          "Uncommon brain tumors", section on 'Pilocytic astrocytoma'
         </a>
         and
         <a class="local">
          'Role of targeted therapies'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Their clinical behavior may be aggressive; this is never observed with hamartomas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allelic chromosomal loss occurs in some pilocytic astrocytomas, suggesting that they are clonal lesions arising from inactivation of a tumor suppressor gene. As an example, loss of chromosome 17q (the location of the neurofibromatosis type 1 [
         <em>
          NF1
         </em>
         ] gene) is demonstrable in some cases, even in patients without NF1 or
         <em>
          NF2
         </em>
         -related schwannomatosis (NF2), suggesting some link between this gene and tumor development [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          BRAF
         </em>
         duplications have been identified in approximately 70 percent of cases [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         OPGs in patients with NF1 exhibit a characteristic loss of neurofibromin (which functions as a negative growth regulator for astrocytes) and increased Ras activation [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The signs and symptoms of OPGs usually develop over a course of months to years and depend upon the location of the tumor.
        </p>
        <p>
         Orbital tumors most often present with proptosis; less frequent findings are strabismus and symptoms similar or identical to spasmus nutans (pendular or dysconjugate nystagmus, torticollis, and head-bobbing) [
         <a href="#rid18">
          18-20
         </a>
         ]. Unilateral visual impairment is a relatively uncommon presenting symptom, possibly due to the young age of these patients at presentation. Funduscopic examination may show edema of the optic disc and/or pallor due to atrophy.
        </p>
        <p>
         Chiasmal and hypothalamic gliomas often present as large masses even though they are typically well differentiated and low grade (most often pilocytic) [
         <a href="#rid2">
          2,10,21
         </a>
         ]. In patients with chiasmal lesions, the chief complaint is usually impaired vision. Obstructive hydrocephalus also may be noted at presentation [
         <a href="#rid10">
          10,22
         </a>
         ]. The diencephalic syndrome, manifested by progressive emaciation and failure to thrive in an apparently alert, cheerful infant, can be seen with hypothalamic gliomas [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2877.html" rel="external">
          "Poor weight gain in children older than two years in resource-abundant settings", section on 'Increased needs'
         </a>
         .)
        </p>
        <p>
         Endocrinopathies due to hypothalamic extension are present in 10 to 20 percent of patients with OPGs. The most frequent is precocious puberty due to involvement of the hypothalamic-pituitary-gonadal axis; this occurs in up to 39 percent of children with neurofibromatosis type 1 (NF1) and chiasmal OPGs [
         <a href="#rid24">
          24
         </a>
         ]. Thus, all children with chiasmal tumors should be screened for endocrine abnormalities.
        </p>
        <p>
         The primary presenting symptoms tend to be different in patients with and without NF1. While patients with sporadic OPG are more likely to present with signs of increased intracranial pressure and hydrocephalus, those with NF1-associated OPGs are more likely to present with precocious puberty [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of OPG should be considered in any child presenting with unexplained visual loss, monocular or asymmetric nystagmus, a diencephalic syndrome, or optic atrophy.
        </p>
        <p>
         The diagnosis is best made by contrast-enhanced magnetic resonance imaging (MRI), which allows visualization of the entire course of the optic nerve and optic pathway. MRI also delineates hypothalamic involvement more clearly than computed tomography (CT). In patients with established tumors who are being followed serially, noncontrast MRI provides similar accuracy in terms of tumor size assessments compared with contrast-enhanced MRI [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Three typical patterns are seen on neuroimaging studies [
         <a href="#rid27">
          27-29
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tubular thickening, tortuosity, or both of the optic nerve  (
         <a class="graphic graphic_diagnosticimage graphicRef100713" href="/z/d/graphic/100713.html" rel="external">
          image 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suprasellar tumor with contiguous chiasmal or optic nerve involvement  (
         <a class="graphic graphic_diagnosticimage graphicRef141018" href="/z/d/graphic/141018.html" rel="external">
          image 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suprasellar tumor with optic tract involvement  (
         <a class="graphic graphic_diagnosticimage graphicRef141021" href="/z/d/graphic/141021.html" rel="external">
          image 3
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The differential diagnosis of masses in the region of the hypothalamus includes craniopharyngioma, glioma, germinoma, teratoma, lymphoma, Langerhans cell histiocytosis, and neurosarcoidosis. Cyst formation is unusual in optic gliomas but may be seen with cases exhibiting extension into the hypothalamic region. The presence of a cyst and calcification within a suprasellar mass is more suggestive but not diagnostic of adamantinomatous craniopharyngioma [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">
          "Causes, presentation, and evaluation of sellar masses"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5210.html" rel="external">
          "Craniopharyngioma"
         </a>
         .)
        </p>
        <p>
         Suprasellar masses without apparent optic nerve extension or optic tract involvement are less likely to be OPGs, and biopsy may be required for diagnosis. Although some experts advocate biopsy of any lesion in the suprasellar region, we recommend that a biopsy be obtained if the lesion does not appear vascular and there is no apparent primary tumor from which the lesion could have metastasized.
        </p>
        <p>
         When performed, biopsies provide an opportunity for molecular studies that may alter management and prognostic understanding in the future. In a study of 72 patients with non-NF1 optic pathway glioma in which a biopsy sample for molecular profiling was available, those patients with unfavorable clinical course (as defined by progression after radiation therapy, multiple systemic therapies, metastasis, or fatal disease) had clear differences in clinical presentation and molecular alterations, pathway activation, and/or expression [
         <a href="#rid31">
          31
         </a>
         ]. Most notably, the presence of
         <em>
          KIAA1549-BRAF
         </em>
         fusion was associated with more aggressive disease.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          CLINICAL COURSE AND PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical behavior of OPGs is unpredictable [
         <a href="#rid32">
          32
         </a>
         ]. Spontaneous regression, malignant degeneration, and metastatic dissemination through ventriculoperitoneal shunts have all been reported. In children, the variable clinical course is more a function of location than specific histology [
         <a href="#rid21">
          21,33
         </a>
         ]. In adults, by contrast, OPGs tend to be histologically anaplastic, displaying aggressive clinical behavior [
         <a href="#rid34">
          34-36
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children with intracranial and intraorbital tumors of the optic nerve have a comparatively better prognosis, with a median survival of more than 15 years [
         <a href="#rid1">
          1
         </a>
         ]. Approximately 5 percent of optic nerve gliomas invade the optic chiasm; locally invasive recurrence can also develop following complete intraorbital excision.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The outcome for patients with chiasmal and postchiasmal gliomas is usually less favorable [
         <a href="#rid37">
          37
         </a>
         ]. However, some children with chiasmal gliomas may survive for long periods without treatment [
         <a href="#rid10">
          10,38
         </a>
         ], and cases of spontaneous regression have been reported, all in patients with neurofibromatosis type 1 (NF1) [
         <a href="#rid39">
          39-41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with OPGs associated with NF1 tend to have a better prognosis, at least in part due to the predominance of anterior lesions. However, compared with patients without NF1, those with NF1 have approximately twice the recurrence rate following complete excision of an intraorbital glioma, but a similar prognosis following radiation of a chiasmal glioma [
         <a href="#rid8">
          8,42,43
         </a>
         ]. Risk factors for recurrent/refractory OPG in children with NF1 include young age (&lt;24 months at time of initial treatment), posterior tumor location, and familial inheritance [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Even with prolonged survival, however, many patients have significant long-term visual impairment [
         <a href="#rid37">
          37,45-47
         </a>
         ]. In a retrospective study of 59 children with sporadic OPGs (median age at diagnosis 2.5 years), 45 percent of patients had 20/40 vision or worse in their best eye at a median follow-up of 5.2 years, including 15 patients (25 percent) with severe bilateral vision loss [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Although the prognosis for survival may be better in NF1 patients with OPGs, significant visual impairment is frequent, and it is unclear whether treatment with either chemotherapy or radiation improves the prognosis for retaining vision in these children [
         <a href="#rid47">
          47,48
         </a>
         ]. Risk factors for vision loss in these patients include posterior tumor location, optic disc abnormalities, and abnormal visual acuity at the time of initial treatment [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         In contrast to children, the clinical course of an OPG in an adult resembles the behavior of the tumor's histology, which is more commonly a malignant glioma. In adults, malignant OPGs can result in rapidly progressive visual loss, and middle-aged or older adults may present with the rapid onset of blindness [
         <a href="#rid49">
          49-52
         </a>
         ]. Tumor invasion into adjacent brain may then become apparent, leading to death within a few months of presentation [
         <a href="#rid53">
          53
         </a>
         ]. Standard radiotherapy and/or chemotherapy of these lesions typically leads to disappointing results [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optimal management of OPGs is controversial. Treatment decisions should take into account the patient's age, the presence or absence of neurofibromatosis type 1 (NF1), and the location of the tumor. A multidisciplinary approach is strongly recommended, with close consultations with the ophthalmologist, radiation oncologist, pediatric oncologist, neuroradiologist, and neurosurgeon.
        </p>
        <p>
         If possible, a period of observation should precede treatment initiation in young patients and those with NF1. Tumor size and visual function should be closely monitored both clinically and by serial brain magnetic resonance imaging (MRI); an untoward change in either clinical status or size on imaging may signal the need for active treatment [
         <a href="#rid32">
          32,55
         </a>
         ]. Adults should be managed aggressively, as dictated by pathology.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Optic nerve tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Observation without specific treatment is appropriate for tumors that exclusively involve the optic nerve until there is evidence of either extension into the optic canal or progressive visual compromise. In patients with symptoms due to visual loss or abnormal eye movements, serial neuro-ophthalmologic examinations and MRI scans can be used to assess tumor progression.
        </p>
        <p>
         A minority of children with isolated intraorbital gliomas and NF1 will experience tumor progression within 5 to 10 years [
         <a href="#rid7">
          7,8,27,42,45,56,57
         </a>
         ]. Chemotherapy is usually the first choice in this situation. If there is progression associated with proptosis and a significant cosmetic problem, and there is poor or no vision in that eye, then surgery should be considered; however, surgery invariably results in complete loss of vision in the involved eye. Radiation therapy (RT) is generally deferred in children with NF1 due to an increased risk of secondary malignancy and other sequelae.
        </p>
        <p>
         In a child without NF1, RT may be considered if there is progressive visual loss or radiographic progression after a trial of chemotherapy. Radiation may prove useful to save, and at times improve, vision in an eye that has not lost vision [
         <a href="#rid58">
          58
         </a>
         ]. Upon further evidence of progression, amputation of the nerve within the orbit may be considered. It has been recommended that resection be performed flush with the chiasm to prevent centripetal extension [
         <a href="#rid59">
          59
         </a>
         ]. However, there are few data supporting this concept.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Posterior tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Noninvasive imaging studies may not be able to differentiate OPGs from other lesions that may require different therapy (eg, craniopharyngiomas, germinomas) [
         <a href="#rid30">
          30
         </a>
         ]. For this reason, a pathologic diagnosis should be established in all cases of pediatric diencephalic tumors except for those patients with NF1, in whom the diagnosis of an OPG is virtually certain. Biopsy of small lesions should be carried out carefully, so that remaining vision is not jeopardized [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
         Following diagnosis, patients can be managed with observation, tumor resection, radiotherapy, chemotherapy, and/or targeted therapy. Although these treatments may improve tumor-related symptoms, there is no evidence that any routine intervention enhances long-term survival.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tumor resection and/or ventricular shunting is indicated when an OPG is causing obstructive hydrocephalus. However, the role of radical resection in other settings is controversial.
        </p>
        <p>
         Traditionally, patients with OPGs have been treated nonsurgically or with conservative surgical approaches due to the morbidity and the uncertain influence of surgical treatment on outcome. A retrospective series examined conservative surgical strategies in 33 patients with OPGs who would have been considered eligible for radical surgery in many centers today, but who were treated with no surgery, with conservative surgery (&lt;50 percent resection), or with biopsy alone, followed by adjuvant therapy with radiation (29 patients) and/or chemotherapy (18 patients) [
         <a href="#rid46">
          46
         </a>
         ]. After a mean follow-up of 11 years, only five of these conservatively treated patients had died (three of tumor progression, one of acute shunt malfunction, and one of intercurrent infection). Twenty-three surviving patients had functional vision in at least one eye, 12 required no endocrine replacement, and 16 were capable of meeting standard academic requirements.
        </p>
        <p>
         There may, however, be benefits to radical resection other than prolongation of survival. These include a delay in the time to disease progression in older children and a delay in the need for RT in younger children [
         <a href="#rid62">
          62,63
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 45 patients with extensive gliomas of the chiasm and third ventricle, 77 percent experienced stabilization or improvement in visual function after radical resection. The surgical mortality was 6 percent [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another series of 16 children with chiasmal or hypothalamic tumors treated with radical resection, three infants died of progressive disease. However, 11 of the other 13 were alive without disease progression 4 to 54 months following radical resection; six did not receive adjuvant chemotherapy or radiation [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the benign histologic appearance of many OPGs, chemotherapy results in surprisingly high response rates. For this reason, chemotherapy is often preferred as initial treatment rather than radiation, especially in children less than age five years, for whom there is a high likelihood of deleterious effects on cognitive function with other treatment modalities [
         <a href="#rid45">
          45,64-68
         </a>
         ]. The use of chemotherapy can often postpone the need for radiation, a delay that may reduce neurocognitive morbidity without compromising survival [
         <a href="#rid45">
          45,69-72
         </a>
         ]. Targeted therapy is also being studied in this setting. (See
         <a class="local">
          'Role of targeted therapies'
         </a>
         below.)
        </p>
        <p>
         The efficacy of this approach in deferring RT was illustrated in a multicenter study of 85 children with progressive OPGs (median age 33 months) who received alternating combinations of chemotherapy every three weeks (
         <a class="drug drug_general" data-topicid="9815" href="/z/d/drug information/9815.html" rel="external">
          procarbazine
         </a>
         /
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         /
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         /
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) [
         <a href="#rid70">
          70
         </a>
         ]. This chemotherapy-first approach was successful in avoiding the use of RT in children in 75 and 61 percent of children at three and five years, respectively. The median interval between the start of therapy and the need for radiation in the 25 children in whom it was delivered was 35 months. Delaying radiation did not jeopardize outcomes; the 89 percent overall survival rate at five years is comparable to that achieved with initial irradiation, and visual outcomes were not dissimilar.
        </p>
        <p>
         Between 40 and 60 percent of patients eventually progress after chemotherapy and require further therapy [
         <a href="#rid45">
          45,69,70
         </a>
         ]. Patients who have OPGs in the setting of NF1 often have indolent disease, and fewer require subsequent therapy.
        </p>
        <p>
         Various combination chemotherapy regimens have been used to treat these tumors. Combinations of
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         and actinomycin D, vincristine and
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         or carboplatin plus
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , or a nitrosourea-based combination regimen are most frequently used [
         <a href="#rid64">
          64-66,69,73,74
         </a>
         ]. The following describes the range of findings.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study, 78 children with newly diagnosed, progressive low-grade gliomas, including 58 with diencephalic tumors, were treated with
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         [
         <a href="#rid69">
          69
         </a>
         ]. Forty-four (56 percent) patients had an objective response to treatment, and the progression-free survival rate at three years was 68 percent. The three-year progression-free survival rate was higher in children five years or younger at the time of treatment (74 versus 39 percent in older children).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a second series, 34 children ranging in age from 4 months to 16 years old (median 45 months) with unresectable low-grade glioma (29 of which were located in the optic pathway) received 10 monthly courses of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         [
         <a href="#rid66">
          66
         </a>
         ]. Twenty-four (70 percent) achieved an objective response, while the remainder had stable disease; no patient required elective radiotherapy. The three-year progression-free survival rate for the 31 previously untreated patients was 78 percent and was significantly higher in children older than 12 months (87 versus 33 percent).
        </p>
        <p>
        </p>
        <p>
         Single agents with evidence of activity against progressive OPG in small studies include
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         and
         <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">
          vinblastine
         </a>
         [
         <a href="#rid75">
          75-77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2292326161">
         <span class="h3">
          Role of targeted therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapies targeting the MAPK pathway have an emerging role in treatment of OPGs, since
         <em>
          BRAF
         </em>
         alterations occur in a high percentage of tumors with pilocytic astrocytoma histology. When to use targeted therapy is controversial, with some advocating its use as a first-line option and others favoring use after treatment failure with more studied therapies (chemotherapy and/or RT) [
         <a href="#rid78">
          78
         </a>
         ]. Clinical trial participation is encouraged.
        </p>
        <p>
         MAPK pathway inhibitors with evidence of activity in OPGs include
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         and
         <a class="drug drug_general" data-topicid="127843" href="/z/d/drug information/127843.html" rel="external">
          selumetinib
         </a>
         (MEK1/MEK2 inhibitors) and
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         (a BRAF inhibitor) [
         <a href="#rid79">
          79,80
         </a>
         ]. Among these options, MEK1/MEK2 inhibition is generally preferred to BRAF inhibition as it avoids paradoxical activation of the MAPK pathway that can occur with direct BRAF inhibitors.
        </p>
        <p>
         Based on available data, it is unknown whether favorable early responses to MEK1/MEK2 inhibitor therapy in OPG will be durable. Nevertheless, for now, targeted therapy for both NF1-related and NF1-unrelated OPG is a promising treatment for progressive tumors that may delay or avoid use of RT or alkylating therapy, both of which are associated with significant toxicities in this setting.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selumetinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="127843" href="/z/d/drug information/127843.html" rel="external">
          Selumetinib
         </a>
         , which is approved by the US Food and Drug Administration for NF1-associated plexiform neurofibromas, is active in both NF1-associated and sporadic OPGs. Supporting evidence includes results of a phase II Pediatric Brain Tumor Consortium trial of selumetinib 25 mg/m
         <sup>
          2
         </sup>
         /dose orally twice daily for up to 26 months in children with recurrent/progressive low-grade gliomas, in which patients with OPG were primarily enrolled in two different strata:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with NF1 – Strata 3 enrolled 25 patients with NF1-associated recurrent/progressive low-grade glioma, including 13 OPGs [
         <a href="#rid81">
          81
         </a>
         ]. No
         <em>
          BRAF
         </em>
         alterations were detected in three patients for whom tissue was available. Ten of 25 patients (40 percent) achieved a sustained complete or partial response, with a median time to partial response of 3.6 months. The two-year progression-free survival was 96 percent. In 10 evaluable patients with OPG, visual acuity improved (20 percent) or was stable (80 percent). The most common grade 3/4 toxicities were creatine phosphokinase (CPK) elevation (10 percent) and maculopapular rash (10 percent). Eight patients required a dose reduction due to adverse effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients without NF1 – Strata 4 enrolled 25 patients with recurrent/progressive sporadic (non-NF1) OPG or hypothalamic low-grade glioma [
         <a href="#rid82">
          82
         </a>
         ]. Among six patients for whom
         <em>
          BRAF
         </em>
         testing was performed, three were positive for a
         <em>
          BRAF-KIAA
         </em>
         gene fusion; all six were negative for
         <em>
          BRAF
         </em>
         V600E point mutation. In the entire strata, two-year progression-free survival was 74 percent; partial response and stable disease were observed in 24 and 56 percent of patients, respectively. The median time to response was 19.7 months, and response did not depend on
         <em>
          BRAF
         </em>
         status. Visual acuity improved in 4 of 19 evaluable patients (21 percent) and remained stable in 13 (68 percent). Grade 3/4 toxicities were uncommon and mostly consisted of CPK elevation, emesis, or hyponatremia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Based on these results, non-
         <em>
          BRAF
         </em>
         V600E OPGs are included as an eligible tumor in ongoing randomized trials of
         <a class="drug drug_general" data-topicid="127843" href="/z/d/drug information/127843.html" rel="external">
          selumetinib
         </a>
         versus
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         /
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         in newly diagnosed or previously untreated pediatric low-grade glioma in patients with and without NF1 (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03871257%3Fterm%3DNF1%26cond%3Dselumetinib%26draw%3D2%26rank%3D9&amp;token=JHlDHVT3V8DQW1O18Wj65BQVQSbT921IuFN8XWeYFJwLwbWzrRPXYr5z4MCDheR9Wp3u4IM0a08Pzts2K5UbvmPGTsyTnyyyKxzJOgCMGV7RFMJzlBqwHoy3AvoE5sTM&amp;TOPIC_ID=5226" target="_blank">
          NCT03871257
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04166409%3Fterm%3DNCT04166409%26draw%3D2%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPNc9mZaHNVPtbvH452O8AYkwdwfkMu7dY%2FjKYh%2FDWPmsIhnnr8xZapxaVtUg%2B49MD8%3D&amp;TOPIC_ID=5226" target="_blank">
          NCT04166409
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Angiogenesis inhibitors
         </strong>
         – There are now a number of reports that have noted qualitative improvement in vision after bevacizumab-based treatment in children with OPGs [
         <a href="#rid83">
          83-86
         </a>
         ], even without radiographic progression [
         <a href="#rid86">
          86
         </a>
         ]. Although the numbers are small, these reports suggest that improvement is significant enough to consider its use, either alone or in conjunction with other therapies, in all patients with OPG and failing vision.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune modulators
         </strong>
         – Immune modulators such as
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         are being explored in pediatric patients who have progressed on standard therapies. In a phase II study of high-dose and low-dose lenalidomide in 74 children with pilocytic astrocytoma or OPG, there were four partial responses in each arm, and low-dose therapy was better tolerated [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3178363295">
         <span class="h3">
          Radiotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with progressive chiasmal OPGs with or without NF1, 5- and 10-year progression-free survival is better in patients who receive radiation. Despite this, the survival rate after 20 years is equivalent to that in patients who have not received radiation. There is also no clear evidence that earlier intervention for chiasmal OPGs changes prognosis [
         <a href="#rid7">
          7,24
         </a>
         ].
        </p>
        <p>
         Nevertheless, external beam radiation therapy (45 to 54 Gy) has been used in patients with progressive tumor to diminish tumor bulk, decrease recurrence rates, prolong recurrence-free survival, reverse the diencephalic syndrome, and improve vision [
         <a href="#rid1">
          1,2,22,88-92
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RT can arrest progressive visual and neurologic impairment, although the maximal effect can take years to be observed. In one retrospective study of 42 OPG patients with median age of 6.6 years (range 1.25 to 19 years), 29 patients were irradiated for progressive disease [
         <a href="#rid88">
          88
         </a>
         ]. A decrease in tumor size at 24 and 60 months was observed in 18 and 46 percent of patients, respectively, with a median time to response of 62 months [
         <a href="#rid88">
          88
         </a>
         ]. Stabilization of or improvement in vision occurred in 81 percent. The 10-year freedom from progression and overall survival rates were 89 and 100 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two separate series evaluated patients with glioma of the optic chiasm or optic nerve who were treated with radiation. After 10 to 13 years of follow-up, the 5-, 10-, and 15-year overall actuarial survival rates were 94 to 96, 81 to 90, and 74 to 90 percent, respectively [
         <a href="#rid92">
          92,93
         </a>
         ]. Fifty-five percent of the patients in one series had a radiation-induced complication, most often involving the pituitary gland [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A contemporary study using fractionated proton therapy to a median of 50.4 Gy (relative biologic effectiveness [RBE]) in 38 pediatric patients achieved 100 percent blindness-free survival if radiation therapy was given early, as defined by initial diagnosis or first salvage therapy [
         <a href="#rid94">
          94
         </a>
         ]. All patients were treated with proton therapy by rationale of reduced collateral normal tissue radiation exposure as compared with photon-based radiation therapy.
        </p>
        <p>
        </p>
        <p>
         The long-term sequelae of RT may be functionally devastating (especially in young children) despite the benefit of disease stabilization and objective tumor shrinkage in the majority of irradiated patients. Significant cognitive and endocrine deficits are most prominent following irradiation in infants [
         <a href="#rid88">
          88
         </a>
         ]. These radiation-induced complications have led to the use of chemotherapy as the initial treatment, so that RT can be deferred as long as possible [
         <a href="#rid56">
          56,95
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6253.html" rel="external">
          "Overview of the management of central nervous system tumors in children", section on 'Long-term morbidity'
         </a>
         and
         <a class="local">
          'Chemotherapy'
         </a>
         above.)
        </p>
        <p>
         Occlusive vascular disease, angiographically similar to moyamoya disease, and usually presenting with ischemic stroke, can also occur following radiation for a chiasmal tumor, particularly in patients with NF1 [
         <a href="#rid95">
          95-98
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1131.html" rel="external">
          "Moyamoya disease and moyamoya syndrome: Etiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
         In one retrospective study of 47 patients treated for optic glioma, moyamoya disease developed in 5 of 28 patients treated with radiation (including three of five patients with NF1) compared with none of 19 who did not receive radiation [
         <a href="#rid97">
          97
         </a>
         ]. A second series documented occlusive vasculopathy in 13 of 69 children with OPGs, at a median of 36 months after radiation treatment [
         <a href="#rid95">
          95
         </a>
         ]. In addition to radiation therapy itself, a major risk factor was NF1.
        </p>
        <p>
         In addition, malignant gliomas can develop in previously irradiated fields [
         <a href="#rid61">
          61,99,100
         </a>
         ]. The use of RT in patients with NF1 is of particular concern because of the development of second primary tumors [
         <a href="#rid100">
          100
         </a>
         ]. In an observational series of 58 patients, 9 of 18 patients (50 percent) developed one or more additional nervous system tumors, and five of these died as a result of the second tumor. By contrast, 8 of 40 patients (20 percent) who were not irradiated for their OPGs developed second nervous system tumors, and no deaths were observed. A more contemporary study reported a threefold increased risk of second nervous system tumors in patients who received RT compared with those who did not [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
         Newer RT techniques (eg, proton beam irradiation and stereotactic radiotherapy) may provide adequate tumor control while reducing collateral radiation exposure to other tissues, contributing to decreasing treatment-related morbidity [
         <a href="#rid94">
          94
         </a>
         ]. Further experience is needed with proton beam therapy to know whether this approach improves long-term outcomes.
        </p>
        <p class="headingAnchor" id="H865956308">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/130511.html" rel="external">
          "Society guideline links: Primary brain tumors"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/117263.html" rel="external">
          "Society guideline links: Neurofibromatosis type 1"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach
         </strong>
         – The optimal management of patients with optic pathway gliomas (OPGs) is uncertain. There are no randomized clinical trials to guide clinical decision-making, and current approaches are based upon observational studies. Our approach is based on tumor location, patient age, and whether or not the patient has neurofibromatosis type 1 (NF1). (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anterior pathway lesions
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children with asymptomatic or minimally symptomatic OPGs arising in the optic nerve, we suggest observation rather than early interventions (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Optic nerve tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In such patients, lesions should be monitored for progression with serial magnetic resonance imaging (MRI) scans and careful neuro-ophthalmologic examinations.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Active treatment is indicated when there is evidence of progression or lesions cause unsightly proptosis or significant visual loss. Chemotherapy is usually the first choice in this situation. Radiation therapy (RT) may be considered if there is progressive visual loss after a trial of chemotherapy. If progression is associated with proptosis and a significant cosmetic problem and there is no vision in that eye, surgery should be considered. However, surgery typically results in complete loss of vision in the involved eye.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chiasmal and hypothalamic tumors
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with NF1
         </strong>
         –
         <strong>
         </strong>
         For patients without significant visual field deficits, we suggest initial observation because of the relatively favorable prognosis in NF1 patients (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Surgery may be required if symptoms of obstructive hydrocephalus are present. (See
         <a class="local">
          'Posterior tumors'
         </a>
         above and
         <a class="local">
          'Surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In children who subsequently have evidence of progression or have significant visual deficits, we suggest chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Targeted therapy with a MEK1/MEK2 inhibitor is an alternative to chemotherapy, and clinical trial participation is encouraged. Surgery may be indicated if it is judged that appropriate resection can relieve pressure on the optic apparatus and thereby improve vision. However, surgical morbidity in this location should not be underestimated. RT should be deferred as long as possible to minimize the effects on the developing central nervous system. (See
         <a class="local">
          'Posterior tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients without NF1
         </strong>
         – In patients without NF1, a biopsy is typically required to determine whether the OPG is a grade 1 pilocytic astrocytoma or another type of tumor. (See
         <a class="local">
          'Posterior tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with a pilocytic astrocytoma who are symptomatic, chemotherapy is preferred as initial treatment in children less than 10 years of age. For older patients, either chemotherapy or RT may be used. MAPK pathway inhibition is an evolving option for tumors with
         <em>
          BRAF
         </em>
         alterations, and clinical trial participation is encouraged. (See
         <a class="local">
          'Role of targeted therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For children with other histologic tumor types, the treatment depends on the type of tumor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adults
         </strong>
         – Adult patients with malignant OPG should be treated as high-grade astrocytomas. (See
         <a class="medical medical_review" href="/z/d/html/5228.html" rel="external">
          "Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5225.html" rel="external">
          "Radiation therapy for high-grade gliomas"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5207.html" rel="external">
          "Initial treatment and prognosis of IDH-wildtype glioblastoma in adults"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Alvord EC Jr, Lofton S. Gliomas of the optic nerve or chiasm. Outcome by patients' age, tumor site, and treatment. J Neurosurg 1988; 68:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenny RT, Laws ER Jr, Younge BR, Rush JA. The neurosurgical management of optic glioma. Results in 104 patients. J Neurosurg 1982; 57:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benes V, Julisová I, Julis I. Our treatment philosophy of gliomas of the anterior visual pathways. Childs Nerv Syst 1990; 6:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu GT, Galetta SL, Rorke LB, et al. Gangliogliomas involving the optic chiasm. Neurology 1996; 46:1669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutton LN, Packer RJ, Rorke LB, et al. Cerebral gangliogliomas during childhood. Neurosurgery 1983; 13:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vajramani GV, Dambatta S, Walker M, Grundy PL. Multiple gangliogliomas of the optic pathway. Br J Neurosurg 2006; 20:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: A longitudinal study. J Pediatr 1994; 125:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997; 41:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor T, Jaspan T, Milano G, et al. Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol 2008; 81:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller NR, Iliff WJ, Green WR. Evaluation and management of gliomas of the anterior visual pathways. Brain 1974; 97:743.
          </a>
         </li>
         <li class="breakAll">
          WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), International Agency for Research on Cancer, 2016.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacob K, Albrecht S, Sollier C, et al. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer 2009; 101:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu J, Deshmukh H, Gutmann RJ, et al. Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 2009; 73:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whittle IR, Mitchener A, Atkinson HD, Wharton SB. Anaplastic progression in low grade glioneural neoplasms. Acta Neuropathol 2002; 104:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez FJ, Ligon AH, Horkayne-Szakaly I, et al. BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol 2012; 71:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau N, Feldkamp MM, Roncari L, et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000; 59:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007; 61:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavery MA, O'Neill JF, Chu FC, Martyn LJ. Acquired nystagmus in early childhood: a presenting sign of intracranial tumor. Ophthalmology 1984; 91:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnoldi KA, Tychsen L. Prevalence of intracranial lesions in children initially diagnosed with disconjugate nystagmus (spasmus nutans). J Pediatr Ophthalmol Strabismus 1995; 32:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koenig SB, Naidich TP, Zaparackas Z. Optic glioma masquerading as spasmus nutans. J Pediatr Ophthalmol Strabismus 1982; 19:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borit A, Richardson EP Jr. The biological and clinical behaviour of pilocytic astrocytomas of the optic pathways. Brain 1982; 105:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeSousa AL, Kalsbeck JE, Mealey J Jr, et al. Optic chiasmatic glioma in children. Am J Ophthalmol 1979; 87:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gropman AL, Packer RJ, Nicholson HS, et al. Treatment of diencephalic syndrome with chemotherapy: growth, tumor response, and long term control. Cancer 1998; 83:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habiby R, Silverman B, Listernick R, Charrow J. Precocious puberty in children with neurofibromatosis type 1. J Pediatr 1995; 126:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Listernick R, Darling C, Greenwald M, et al. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 1995; 127:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maloney E, Perez FA, Iyer RS, et al. Non-inferiority of a non-gadolinium-enhanced magnetic resonance imaging follow-up protocol for isolated optic pathway gliomas. Pediatr Radiol 2022; 52:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fletcher WA, Imes RK, Hoyt WF. Chiasmal gliomas: appearance and long-term changes demonstrated by computerized tomography. J Neurosurg 1986; 65:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jakobiec FA, Depot MJ, Kennerdell JS, et al. Combined clinical and computed tomographic diagnosis of orbital glioma and meningioma. Ophthalmology 1984; 91:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imes RK, Hoyt WF. Magnetic resonance imaging signs of optic nerve gliomas in neurofibromatosis 1. Am J Ophthalmol 1991; 111:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbaro NM, Rosenblum ML, Maitland CG, et al. Malignant optic glioma presenting radiologically as a "cystic" suprasellar mass: case report and review of the literature. Neurosurgery 1982; 11:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li X, Moreira DC, Bag AK, et al. The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma. Neuro Oncol 2023; 25:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shuper A, Horev G, Kornreich L, et al. Visual pathway glioma: an erratic tumour with therapeutic dilemmas. Arch Dis Child 1997; 76:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rush JA, Younge BR, Campbell RJ, MacCarty CS. Optic glioma. Long-term follow-up of 85 histopathologically verified cases. Ophthalmology 1982; 89:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton AM, Garner A, Tripathi RC, Sanders MD. Malignant optic nerve glioma. Report of a case with electron microscope study. Br J Ophthalmol 1973; 57:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibberd FB, Miller TN, Morgan AD. Glioblastoma of the optic chiasm. Br J Ophthalmol 1973; 57:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoyt WF, Meshel LG, Lessell S, et al. Malignant optic glioma of adulthood. Brain 1973; 96:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wan MJ, Ullrich NJ, Manley PE, et al. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. J Neurooncol 2016; 129:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Listernick R, Charrow J, Gutmann DH. Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet 1999; 89:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venes JL, Latack J, Kandt RS. Postoperative regression of opticochiasmatic astrocytoma: a case for expectant therapy. Neurosurgery 1984; 15:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brzowski AE, Bazan C 3rd, Mumma JV, Ryan SG. Spontaneous regression of optic glioma in a patient with neurofibromatosis. Neurology 1992; 42:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perilongo G, Moras P, Carollo C, et al. Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: a real possibility. J Child Neurol 1999; 14:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Listernick R, Charrow J, Greenwald MJ, Esterly NB. Optic gliomas in children with neurofibromatosis type 1. J Pediatr 1989; 114:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deliganis AV, Geyer JR, Berger MS. Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma. Neurosurgery 1996; 38:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotch C, Avery R, Getz KD, et al. Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1. Neuro Oncol 2022; 24:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janss AJ, Grundy R, Cnaan A, et al. Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. Cancer 1995; 75:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutton LN, Molloy PT, Sernyak H, et al. Long-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery. J Neurosurg 1995; 83:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalla Via P, Opocher E, Pinello ML, et al. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro Oncol 2007; 9:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno L, Bautista F, Ashley S, et al. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer 2010; 46:2253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spoor TC, Kennerdell JS, Zorub D, Martinez AJ. Progressive visual loss due to glioblastoma: normal neuroroentgenorgraphic studies. Arch Neurol 1981; 38:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spoor TC, Kennerdell JS, Martinez AJ, Zorub D. Malignant gliomas of the optic nerve pathways. Am J Ophthalmol 1980; 89:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudd A, Rees JE, Kennedy P, et al. Malignant optic nerve gliomas in adults. J Clin Neuroophthalmol 1985; 5:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dario A, Iadini A, Cerati M, Marra A. Malignant optic glioma of adulthood. Case report and review of the literature. Acta Neurol Scand 1999; 100:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taphoorn MJ, de Vries-Knoppert WA, Ponssen H, Wolbers JG. Malignant optic glioma in adults. Case report. J Neurosurg 1989; 70:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albers GW, Hoyt WF, Forno LS, Shratter LA. Treatment response in malignant optic glioma of adulthood. Neurology 1988; 38:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly JP, Weiss AH. Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1. Neuro Oncol 2013; 15:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Packer RJ, Savino PJ, Bilaniuk LT, et al. Chiasmatic gliomas of childhood. A reappraisal of natural history and effectiveness of cranial irradiation. Childs Brain 1983; 10:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Packer RJ, Bilaniuk LT, Cohen BH, et al. Intracranial visual pathway gliomas in children with neurofibromatosis. Neurofibromatosis 1988; 1:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierce SM, Barnes PD, Loeffler JS, et al. Definitive radiation therapy in the management of symptomatic patients with optic glioma. Survival and long-term effects. Cancer 1990; 65:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen ME, Duffner PK. Optic pathway tumors. Neurol Clin 1991; 9:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott EW, Mickle JP. Pediatric diencephalic gliomas--a review of 18 cases. Pediatr Neurosci 1987; 13:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman HJ, Humphreys RP, Drake JM, et al. Optic pathway/hypothalamic gliomas: a dilemma in management. Pediatr Neurosurg 1993; 19:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wisoff JH, Abbott R, Epstein F. Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood. J Neurosurg 1990; 73:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konovalov A, Gorelyshev S, Serova N. Surgery of giant gliomas of chiasma and IIIrd ventricle. Acta Neurochir (Wien) 1994; 130:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Packer RJ, Sutton LN, Bilaniuk LT, et al. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update. Ann Neurol 1988; 23:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petronio J, Edwards MS, Prados M, et al. Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg 1991; 74:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 2002; 20:4209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friehs GM, Park MC, Goldman MA, et al. Stereotactic radiosurgery for functional disorders. Neurosurg Focus 2007; 23:E3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li G, Patil C, Adler JR, et al. CyberKnife rhizotomy for facetogenic back pain: a pilot study. Neurosurg Focus 2007; 23:E2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997; 86:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laithier V, Grill J, Le Deley MC, et al. Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol 2003; 21:4572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacaze E, Kieffer V, Streri A, et al. Neuropsychological outcome in children with optic pathway tumours when first-line treatment is chemotherapy. Br J Cancer 2003; 89:2038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riva D, Massimino M, Giorgi C, et al. Cognition before and after chemotherapy alone in children with chiasmatic-hypothalamic tumors. J Neurooncol 2009; 92:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moghrabi A, Friedman HS, Burger PC, et al. Carboplatin treatment of progressive optic pathway gliomas to delay radiotherapy. J Neurosurg 1993; 79:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamberlain MC. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. Arch Neurol 1995; 52:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cappellano AM, Petrilli AS, da Silva NS, et al. Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol 2015; 121:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 2012; 30:1358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lassaletta A, Scheinemann K, Zelcer SM, et al. Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. J Clin Oncol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooney T, Yeo KK, Kline C, et al. Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. Neurooncol Pract 2020; 7:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller C, Guillaume D, Dusenbery K, et al. Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response. J Neurosurg Pediatr 2017; 19:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Upadhyaya SA, Robinson GW, Harreld JH, et al. Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases. Childs Nerv Syst 2018; 34:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 2019; 20:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fangusaro J, Onar-Thomas A, Poussaint TY, et al. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro Oncol 2021; 23:1777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avery RA, Hwang EI, Jakacki RI, Packer RJ. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol 2014; 132:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hwang EI, Jakacki RI, Fisher MJ, et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 2013; 60:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okada K, Yamasaki K, Tanaka C, et al. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors. Jpn J Clin Oncol 2013; 43:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamasaki F, Takano M, Yonezawa U, et al. Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review. Childs Nerv Syst 2020; 36:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warren KE, Vezina G, Krailo M, et al. Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group. J Clin Oncol 2023; 41:3374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tao ML, Barnes PD, Billett AL, et al. Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome. Int J Radiat Oncol Biol Phys 1997; 39:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong JY, Uhl V, Wara WM, Sheline GE. Optic gliomas. A reanalysis of the University of California, San Francisco experience. Cancer 1987; 60:1847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dosoretz DE, Blitzer PH, Wang CC, Linggood RM. Management of glioma of the optic nerve and/or chiasm: an analysis of 20 cases. Cancer 1980; 45:1467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harter DJ, Caderao JB, Leavens ME, Young SE. Radiotherapy in the management of primary gliomas involving the intracranial optic nerves and chiasm. Int J Radiat Oncol Biol Phys 1978; 4:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovalic JJ, Grigsby PW, Shepard MJ, et al. Radiation therapy for gliomas of the optic nerve and chiasm. Int J Radiat Oncol Biol Phys 1990; 18:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flickinger JC, Torres C, Deutsch M. Management of low-grade gliomas of the optic nerve and chiasm. Cancer 1988; 61:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanania AN, Paulino AC, Ludmir EB, et al. Early radiotherapy preserves vision in sporadic optic pathway glioma. Cancer 2021; 127:2358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grill J, Couanet D, Cappelli C, et al. Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol 1999; 45:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajakulasingam K, Cerullo LJ, Raimondi AJ. Childhood moyamoya syndrome. Postradiation pathogenesis. Childs Brain 1979; 5:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kestle JR, Hoffman HJ, Mock AR. Moyamoya phenomenon after radiation for optic glioma. J Neurosurg 1993; 79:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ullrich NJ, Robertson R, Kinnamon DD, et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology 2007; 68:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dirks PB, Jay V, Becker LE, et al. Development of anaplastic changes in low-grade astrocytomas of childhood. Neurosurgery 1994; 34:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006; 24:2570.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5226 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3275755" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Gliomas of the optic nerve or chiasm. Outcome by patients' age, tumor site, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7108594" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The neurosurgical management of optic glioma. Results in 104 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2340532" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Our treatment philosophy of gliomas of the anterior visual pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8649567" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Gangliogliomas involving the optic chiasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6888690" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cerebral gangliogliomas during childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17439099" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Multiple gangliogliomas of the optic pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8021787" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9029062" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18796556" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Radiological classification of optic pathway gliomas: experience of a modified functional classification system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4434191" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Evaluation and management of gliomas of the anterior visual pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4434191" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Evaluation and management of gliomas of the anterior visual pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19603027" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19794125" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12212544" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Anaplastic progression in low grade glioneural neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22892521" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11005256" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17387725" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6739045" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Acquired nystagmus in early childhood: a presenting sign of intracranial tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8531033" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prevalence of intracranial lesions in children initially diagnosed with disconjugate nystagmus (spasmus nutans)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7069562" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Optic glioma masquerading as spasmus nutans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7066671" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The biological and clinical behaviour of pilocytic astrocytomas of the optic pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/107806" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Optic chiasmatic glioma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9655307" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Treatment of diencephalic syndrome with chemotherapy: growth, tumor response, and long term control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7869193" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Precocious puberty in children with neurofibromatosis type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7472822" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34751813" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Non-inferiority of a non-gadolinium-enhanced magnetic resonance imaging follow-up protocol for isolated optic pathway gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3088222" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Chiasmal gliomas: appearance and long-term changes demonstrated by computerized tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6709328" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Combined clinical and computed tomographic diagnosis of orbital glioma and meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1903904" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Magnetic resonance imaging signs of optic nerve gliomas in neurofibromatosis 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6298650" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Malignant optic glioma presenting radiologically as a "cystic" suprasellar mass: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36260562" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9135269" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Visual pathway glioma: an erratic tumour with therapeutic dilemmas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6818504" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Optic glioma. Long-term follow-up of 85 histopathologically verified cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4707622" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Malignant optic nerve glioma. Report of a case with electron microscope study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4361475" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Glioblastoma of the optic chiasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4695718" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Malignant optic glioma of adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27311725" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10469435" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Intracranial gliomas in neurofibromatosis type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6435008" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Postoperative regression of opticochiasmatic astrocytoma: a case for expectant therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1549238" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Spontaneous regression of optic glioma in a patient with neurofibromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10385841" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: a real possibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2497236" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Optic gliomas in children with neurofibromatosis type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8727140" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35018469" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7842408" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7674005" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Long-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17704361" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20400294" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7469853" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Progressive visual loss due to glioblastoma: normal neuroroentgenorgraphic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6243868" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Malignant gliomas of the optic nerve pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3001150" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Malignant optic nerve gliomas in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10536925" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Malignant optic glioma of adulthood. Case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2643688" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Malignant optic glioma in adults. Case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3386825" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Treatment response in malignant optic glioma of adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24101736" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6661937" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Chiasmatic gliomas of childhood. A reappraisal of natural history and effectiveness of cranial irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3152473" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Intracranial visual pathway gliomas in children with neurofibromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2104571" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Definitive radiation therapy in the management of symptomatic patients with optic glioma. Survival and long-term effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1944110" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Optic pathway tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3332816" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Pediatric diencephalic gliomas--a review of 18 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8329303" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Optic pathway/hypothalamic gliomas: a dilemma in management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2213155" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7725945" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Surgery of giant gliomas of chiasma and IIIrd ventricle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3345069" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1901597" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12377964" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : High response rate to cisplatin/etoposide regimen in childhood low-grade glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18081480" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Stereotactic radiosurgery for functional disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18081475" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : CyberKnife rhizotomy for facetogenic back pain: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9126887" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14673044" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14647135" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Neuropsychological outcome in children with optic pathway tumours when first-line treatment is chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19005618" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cognition before and after chemotherapy alone in children with chiasmatic-hypothalamic tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8331404" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Carboplatin treatment of progressive optic pathway gliomas to delay radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7733847" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25366366" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22393086" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27573663" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32257279" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28009226" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29392423" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31151904" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33631016" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24232489" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22976922" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24002900" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31701281" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37126770" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9336136" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3652011" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Optic gliomas. A reanalysis of the University of California, San Francisco experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7357527" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Management of glioma of the optic nerve and/or chiasm: an analysis of 20 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/101490" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Radiotherapy in the management of primary gliomas involving the intracranial optic nerves and chiasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2323979" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Radiation therapy for gliomas of the optic nerve and chiasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3338030" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Management of low-grade gliomas of the optic nerve and chiasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33739455" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Early radiotherapy preserves vision in sporadic optic pathway glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10072056" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/477462" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Childhood moyamoya syndrome. Postradiation pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8315466" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Moyamoya phenomenon after radiation for optic glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17372129" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Moyamoya following cranial irradiation for primary brain tumors in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8121571" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Development of anaplastic changes in low-grade astrocytomas of childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16735710" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
